(Q22252869)

PubMed

PubMed publication ID

15977315

Mental Retardation and Developmental Disabilities Research Reviews

29 March 2023

language of work or name

English

0 references

publication date

2005

0 references

published in

0 references

volume

11

0 references

issue

2

0 references

page(s)

149-155

0 references

cites work

Piracetam therapy does not enhance cognitive functioning in children with down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

Down syndrome and Alzheimer disease: response to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

TREATMENT OF DOWN'S SYNDROME WITH THE "U" SERIES OF DRUGS

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Cholinergic function and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Regulation of mRNA stability in the nervous system and beyond

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Selenium therapy in Down syndrome (DS): a theory and a clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Dosage effect of SOD-A gene in 21-trisomic cells

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

The effect of vasopressin treatment on learning in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Overexpression of copper-zinc superoxide dismutase in trisomy 21.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Superoxide dismutase activities of blood platelets in trisomy 21

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Plastic surgical management of children with Down's syndrome: indications and results

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Fact and fantasy: psychosocial consequences of facial surgery in 24 Down syndrome children

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Lipid peroxides in blood plasma and enzymatic antioxidative defence of erythrocytes in Down's syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

5-Hydroxytryptophan and sleep in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Trisomy 21 (Down's Syndrome) glutathione peroxidase, hexose monophosphate shunt and I.Q

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Oown's syndrome fetal brain

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Plastic surgery on children with Down syndrome: parents' perceptions of physical, personal, and social functioning

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Enhanced DNA repair in lymphocytes of Down syndrome patients: the influence of zinc nutritional supplementation

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Between 'desperation' and disability rights: a narrative analysis of complementary/alternative medicine use by parents for children with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Use of megadoses of vitamins with minerals in Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Infection and immunity in Down syndrome: a trial of long-term low oral doses of zinc

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

The effects of piracetam on cognitive performance in a mouse model of Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

SICCACELL TREATMENT IN MONGOLISM

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Blood-serotonin deficiency in Down's syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Facial plastic surgery for Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Thymic hormone deficiency in normal ageing and Down's syndrome: is there a primary failure of the thymus?

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Cholinergic therapy for Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Amyloid, the presenilins and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Biomarkers of oxidative stress are significantly elevated in Down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Reactive Oxygen Species and Their Contribution to Pathology in Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Nutritional supplementation in Down syndrome: theoretical considerations and current status

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Effect of vitamin E on chromosomal aberrations in lymphocytes from patients with Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Can nutritional supplements help mentally retarded children? an exploratory study.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Effect of megavitamin treatment on mental performance and plasma vitamin B6 concentrations in mentally retarded young adults.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Speech intelligibility after partial glossectomy in children with Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Social perceptions of the effects of Down syndrome facial surgery: a school-based study of ratings by normal adolescents

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Enzymes of Leukocyte Oxidative Metabolism in Down's Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Low superoxide levels in blood phagocytic cells in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Enzymes point way to potential Alzheimer's therapies.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Parental opinions about facial plastic surgery for individuals with down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Effects of Donepezil on Cognitive Functioning in Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Communicating with pediatricians about complementary/alternative medicine: perspectives from parents of children with down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021

Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders

1 reference

https://api.crossref.org/works/10.1002%2FMRDD.20063

7 January 2021